| Literature DB >> 31682557 |
Lea Heberlein-Larson1, Leah D Gillis2, Andrea Morrison3, Blake Scott3, Mary Cook2, Andrew Cannons1, Elesi Quaye2, Stephen White2, Marshall Cone1, Valerie Mock4, Jarad Schiffer5, David Lonsway6, Marla Petway7, Aaron Otis8, Danielle Stanek3, Janet Hamilton3, Susanne Crowe4.
Abstract
The emergence of Zika virus in the Americas in 2015 and its association with birth defects and other adverse health outcomes triggered an unprecedented public health response and a demand for testing. In 2016, when Florida exceeded state public health laboratory capacity for diagnostic testing, the state formed partnerships with federal and commercial laboratories. Eighty-two percent of the testing (n = 33 802 of 41 008 specimens) by the laboratory partners, including Florida's Bureau of Public Health Laboratories (BPHL; n = 13 074), a commercial laboratory (n = 19 214), and the Centers for Disease Control and Prevention (CDC; n = 1514), occurred from July through November 2016, encompassing the peak period of local transmission. These partnerships allowed BPHL to maintain acceptable test turnaround times of 1 to 4 days for nucleic acid testing and 3 to 7 days for serologic testing. Lessons learned from this response to inform future outbreaks included the need for early planning to establish outside partnerships, adding specimen triage strategies to surge plans, and integrating state and CDC information systems.Entities:
Keywords: disease outbreaks; emerging infectious diseases; laboratory; public health; public health systems; testing
Mesh:
Year: 2019 PMID: 31682557 PMCID: PMC6832035 DOI: 10.1177/0033354919867720
Source DB: PubMed Journal: Public Health Rep ISSN: 0033-3549 Impact factor: 2.792